氢化可的松治疗重症社区获得性肺炎
这项3期多中心双盲随机对照试验纳入因重症社区获得性肺炎入住ICU的成人,随机接受静脉氢化可的松(每日200 mg,根据临床改善用4或7天,随后减量,总疗程8或14天)或安慰剂,均接受抗生素和支持治疗等标准治疗。第二次计划中期分析后试验停止,共800例随机化,795例纳入分析。28天死亡:氢化可的松组400例中25例(6.2%,95%CI 3.9–8.6)vs 安慰剂组395例中47例(11.9%,95%CI 8.7–15.1),绝对差异-5.6个百分点(95%CI -9.6至-1.7;P=0.006)。基线未机械通气者气管插管:氢化可的松组222例中40例(18.0%)vs 安慰剂组220例中65例(29.5%)(HR 0.59;95%CI 0.40–0.86);基线未用血管升压药者28天内启用:氢化可的松组359例中55例(15.3%)vs 安慰剂组344例中86例(25.0%)(HR 0.59;95%CI 0.43–0.82)。两组医院获得性感染和消化道出血频率相似;氢化可的松组治疗第一周每日胰岛素用量更高。
要点
- ICU重症社区获得性肺炎成人:氢化可的松组28天死亡6.2%(25/400)vs 安慰剂组11.9%(47/395),绝对差异-5.6个百分点(95%CI -9.6至-1.7;P=0.006)。
- 基线未机械通气者气管插管:氢化可的松组18.0%(40/222)vs 安慰剂组29.5%(65/220),HR 0.59(95%CI 0.40–0.86)。
- 基线未用血管升压药者28天内启用升压药:氢化可的松组15.3%(55/359)vs 安慰剂组25.0%(86/344),HR 0.59(95%CI 0.43–0.82)。
- 氢化可的松方案:静脉每日200 mg,根据临床改善用4或7天,随后减量,总疗程8或14天;所有患者均接受抗生素和支持治疗等标准治疗。
- 两组医院获得性感染和消化道出血频率相似;氢化可的松组治疗第一周每日胰岛素用量更高。
适用人群与场景
- 因重症社区获得性肺炎入住ICU的成人,随机接受静脉氢化可的松或安慰剂,所有患者均接受抗生素和支持治疗等标准治疗。
处置流程与药物剂量
- 静脉氢化可的松每日200 mg,根据临床改善用4或7天,随后减量,总疗程8或14天。
- 所有患者接受标准治疗,包括抗生素和支持治疗。
研究设计与关键结果
- 3期多中心双盲随机对照试验,第二次计划中期分析后试验停止;共800例随机化,795例纳入分析(氢化可的松组400例,安慰剂组395例)。
- 28天死亡:氢化可的松组25/400(6.2%;95%CI 3.9–8.6)vs 安慰剂组47/395(11.9%;95%CI 8.7–15.1),绝对差异-5.6个百分点(95%CI -9.6至-1.7;P=0.006)。
- 基线未机械通气者气管插管:氢化可的松组40/222(18.0%)vs 安慰剂组65/220(29.5%),HR 0.59(95%CI 0.40–0.86)。
- 基线未用血管升压药者28天内启用:氢化可的松组55/359(15.3%)vs 安慰剂组86/344(25.0%),HR 0.59(95%CI 0.43–0.82)。
- 医院获得性感染和消化道出血频率两组相似;氢化可的松组治疗第一周每日胰岛素用量更高。
证据类型、等级与局限
- 证据类型:3期多中心双盲随机对照试验(CAPE COD,ClinicalTrials.gov NCT02517489),由法国卫生部资助。
- 局限:原文未报告局限性
对床旁实践的改变
- 对ICU重症社区获得性肺炎成人,作者结论为接受氢化可的松者28天死亡风险低于安慰剂组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear.
METHODS: In this phase 3, multicenter, double-blind, randomized, controlled trial, we assigned adults who had been admitted to the intensive care unit (ICU) for severe community-acquired pneumonia to receive intravenous hydrocortisone (200 mg daily for either 4 or 7 days as determined by clinical improvement, followed by tapering for a total of 8 or 14 days) or to receive placebo. All the patients received standard therapy, including antibiotics and supportive care. The primary outcome was death at 28 days.
RESULTS: A total of 800 patients had undergone randomization when the trial was stopped after the second planned interim analysis. Data from 795 patients were analyzed. By day 28, death had occurred in 25 of 400 patients (6.2%; 95% confidence interval [CI], 3.9 to 8.6) in the hydrocortisone group and in 47 of 395 patients (11.9%; 95% CI, 8.7 to 15.1) in the placebo group (absolute difference, -5.6 percentage points; 95% CI, -9.6 to -1.7; P = 0.006). Among the patients who were not undergoing mechanical ventilation at baseline, endotracheal intubation was performed in 40 of 222 (18.0%) in the hydrocortisone group and in 65 of 220 (29.5%) in the placebo group (hazard ratio, 0.59; 95% CI, 0.40 to 0.86). Among the patients who were not receiving vasopressors at baseline, such therapy was initiated by day 28 in 55 of 359 (15.3%) of the hydrocortisone group and in 86 of 344 (25.0%) in the placebo group (hazard ratio, 0.59; 95% CI, 0.43 to 0.82). The frequencies of hospital-acquired infections and gastrointestinal bleeding were similar in the two groups; patients in the hydrocortisone group received higher daily doses of insulin during the first week of treatment.
CONCLUSIONS: Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. (Funded by the French Ministry of Health; CAPE COD ClinicalTrials.gov number, NCT02517489.).
参考来源
- Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med. 2023. PMID: 36942789. doi:10.1056/NEJMoa2215145
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。